NASH Question: From the little I know, which is even less than I thought, the "gold standard" check of whether a liver disease treatment works is when it achieves a reduction in fibrosis. And as I understand it, the results of our 350 mg trial suggest that this MIGHT be the case, but they have yet to confirm any actual physical decrease in the fatty fibrosis tissue.

So if all of that assuming is correct, my question is - could we (Cytodyn) have done any research on the reduction of fibrosis in their Phase 2 700 mg NASH trial? Can they detect such a thing via an imaging technology (CAT/MRI/X-ray) or do they have to do an actual physical biopsy?

I'm wondering because - of all our current studies, everyone seems the most excited about NASH. But the only real way to get really excited about NASH results is if we have physical proof of fibrosis. Correct?